FY2023 EPS Estimates for Yield10 Bioscience, Inc. (NASDAQ:YTEN) Cut by Analyst

Yield10 Bioscience, Inc. (NASDAQ:YTENFree Report) – HC Wainwright decreased their FY2023 earnings per share estimates for Yield10 Bioscience in a report released on Thursday, November 16th. HC Wainwright analyst A. Dayal now forecasts that the specialty chemicals company will post earnings per share of ($2.04) for the year, down from their previous estimate of ($1.93). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Yield10 Bioscience’s current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Yield10 Bioscience’s Q4 2023 earnings at ($0.23) EPS, FY2024 earnings at ($0.43) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.14) EPS.

Other equities research analysts have also recently issued research reports about the company. Lake Street Capital reduced their price objective on Yield10 Bioscience from $12.00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, August 16th. Maxim Group reissued a “hold” rating on shares of Yield10 Bioscience in a research note on Thursday, November 16th.

Read Our Latest Research Report on YTEN

Yield10 Bioscience Price Performance

Shares of YTEN opened at $0.25 on Monday. Yield10 Bioscience has a 1 year low of $0.21 and a 1 year high of $4.19. The company has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.10 and a beta of 1.84. The business has a 50-day moving average of $0.32 and a 200-day moving average of $1.31.

Institutional Trading of Yield10 Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in YTEN. Grand Wealth Management LLC purchased a new position in Yield10 Bioscience during the first quarter worth about $78,000. Millennium Management LLC purchased a new stake in Yield10 Bioscience during the 2nd quarter valued at about $132,000. Finally, Jane Street Group LLC purchased a new stake in Yield10 Bioscience during the 1st quarter valued at about $72,000. 10.83% of the stock is currently owned by institutional investors.

About Yield10 Bioscience

(Get Free Report)

Yield10 Bioscience, Inc operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions.

Read More

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.